The Experts below are selected from a list of 81 Experts worldwide ranked by ideXlab platform
Toshihiko Hirano - One of the best experts on this subject based on the ideXlab platform.
-
comparison of suppressive potency between Prednisolone and Prednisolone Sodium Succinate against mitogen induced blastogenesis of human peripheral blood mononuclear cells in vitro
Journal of Pharmacy and Pharmacology, 2001Co-Authors: Kentaro Sugiyama, Tomie Kawada, Hiroshi Sato, Toshihiko HiranoAbstract:: Clinically, both Prednisolone and Prednisolone Sodium Succinate are widely used as immunosuppressive agents for the treatment of various allergic disorders. However, whether Prednisolone Sodium Succinate itself has immunosuppressive or anti-inflammatory effects is unclear, and Prednisolone Sodium Succinate may exhibit its efficacy only after hydrolytic conversion to Prednisolone in-vivo. If this is the case, the impairment of Prednisolone Sodium Succinate conversion to Prednisolone in some clinical conditions may attenuate the efficacy of Prednisolone Sodium Succinate. We therefore compared the pharmacological efficacy of Prednisolone with that of Prednisolone Sodium Succinate in-vitro using human peripheral blood mononuclear cells (PBMCs). PBMCs were obtained from 5 healthy subjects and 1 patient with pneumonia. The cells were incubated in the presence of concanavalin A and the cell growth was estimated by 3-(4,5-dimethyl thiazo-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Both Prednisolone and Prednisolone Sodium Succinate dose-dependently suppressed PBMC blastogenesis. Mean (s.d.) Prednisolone and Prednisolone Sodium Succinate IC50 (concentration of drug that gave 50% inhibition of cell growth) values were 580.0 (1037.9) and 3237.1 (4627.3) nM, respectively. The ratio of Prednisolone IC50/Prednisolone Sodium Succinate IC50 ranged from 0.005 to 0.230. Thus, Prednisolone Sodium Succinate potency was markedly lower than that of Prednisolone. After incubation of PBMCs with 100 microM Prednisolone Sodium Succinate, 22.7-42.9 microM Prednisolone was liberated into the culture medium, as determined by HPLC. The ratio of Prednisolone liberation from Prednisolone Sodium Succinate was not affected by the presence of fetal bovine serum or PBMC, or both, in the culture medium. These results suggested that the PBMC-suppressive effects of Prednisolone Sodium Succinate might be due, at least partially, to Prednisolone liberated from Prednisolone Sodium Succinate into the culture medium. Prednisolone Sodium Succinate can be converted to Prednisolone in the absence of serum or PBMCs, but the ratio of this conversion was very slow (t(1/2) > 4 days). Therefore, impairment of the enzymatic conversion of Prednisolone Sodium Succinate to Prednisolone in some pathological conditions such as liver diseases may result in attenuation of the clinical efficacy of Prednisolone Sodium Succinate.
Lekeux Pierre - One of the best experts on this subject based on the ideXlab platform.
-
Efficiency of 5-Hydroxytryptamine receptor blockade as therapeutic measure during acute respiratory distress syndrome in double-muscled cattle
'Wiley', 1993Co-Authors: Génicot Bruno, Mouligneau Frédéric, Lindsey, James K., Lambert Philippe, Close Roland, Lekeux PierreAbstract:During this investigation, which involved 58 Belgian White and Blue double-muscled calves affected by a naturally occurring Acute Respiratory Distress Syndrome, the clinical efficiency of a 5-HT2 receptor blockade with metrenperone (group A) was compared to the efficiency of a nonsteroidal (flunixine meglumine — group B) and a steroidal (Prednisolone Sodium Succinate — group C) antiinflammatory drug. Each animal of this trial was treated with ceftiofur Sodium as antimicrobial agent. A clinical score and a breathing score were calculated at each step of the investigation period, i. e. before (T0) and 1 hour (T1), 12 hours (H), 24H, 48H and 168H (T3) after the first treatment, the interval 12H–48H being considered as period T2. Three clinical parameters were also taken into account separately: rectal and peripheral temperatures and heart rate. A significant improvement of the clinical score was registered at T2 in group A and at T3 in groups A and B, while this score did not significantly change in group C. In group A, the breathing score was significantly improved at T2 and T3, but not in groups B and C. Peripheral and rectal temperatures recorded at T1 were, in group A, significantly increased and decreased respectively, but not significantly changed in groups B and C. The proportions requiring change of treatment during the investigation period were significantly (P = 0.022) different in the three groups, being 5.6, 21.4 and 50.0% in groups A, B and C respectively. In conclusion, compared with flunixine meglumine and Prednisolone Sodium Succinate, metrenperone significantly reduced the proportion requiring treatment change in double-muscled calves affected by a naturally occurring Acute Respiratory Distress Syndrome. Furthermore, the respiratory and clinical status of the animals subjected to such a 5-HT2 receptor blockade improved more quickly
-
Efficiency of 5-Hydroxytryptamine Receptor Blockade as Therapeutic Measure During Acute Respiratory Distress Syndrome in Double-Muscled Cattle
1993Co-Authors: Génicot Bruno, Mouligneau Frédéric, Lindsey, James K., Lambert Philippe, Close Roland, Lekeux PierreAbstract:During this investigation, which involved 58 Belgian White and Blue double-muscled calves affected by a naturally occurring Acute Respiratory Distress Syndrome, the clinical efficiency of a 5-HT2 receptor blockade with metrenperone (group A) was compared to the efficiency of a non-steroidal (flunixine meglumine--group B) and a steroidal (Prednisolone Sodium Succinate--group C) antiinflammatory drug. Each animal of this trial was treated with ceftiofur Sodium as antimicrobial agent. A clinical score and a breathing score were calculated at each step of the investigation period, i.e. before (T0) and 1 hour (T1), 12 hours (H), 24 H, 48H and 168 H (T3) after the first treatment, the interval 12H-48H being considered as period T2. Three clinical parameters were also taken into account separately: rectal and peripheral temperatures and heart rate. A significant improvement of the clinical score was registered at T2 in group A and at T3 in groups A and B, while this score did not significantly change in group C. In group A, the breathing score was significantly improved at T2 and T3, but not in groups B and C. Peripheral and rectal temperatures recorded at T1 were, in group A, significantly increased and decreased respectively, but not significantly changed in groups B and C. The proportions requiring change of treatment during the investigation period were significantly (P = 0.022) different in the three groups, being 5.6, 21.4 and 50.0% in groups A, B and C respectively.(ABSTRACT TRUNCATED AT 250 WORDS)Peer reviewe
Kentaro Sugiyama - One of the best experts on this subject based on the ideXlab platform.
-
comparison of suppressive potency between Prednisolone and Prednisolone Sodium Succinate against mitogen induced blastogenesis of human peripheral blood mononuclear cells in vitro
Journal of Pharmacy and Pharmacology, 2001Co-Authors: Kentaro Sugiyama, Tomie Kawada, Hiroshi Sato, Toshihiko HiranoAbstract:: Clinically, both Prednisolone and Prednisolone Sodium Succinate are widely used as immunosuppressive agents for the treatment of various allergic disorders. However, whether Prednisolone Sodium Succinate itself has immunosuppressive or anti-inflammatory effects is unclear, and Prednisolone Sodium Succinate may exhibit its efficacy only after hydrolytic conversion to Prednisolone in-vivo. If this is the case, the impairment of Prednisolone Sodium Succinate conversion to Prednisolone in some clinical conditions may attenuate the efficacy of Prednisolone Sodium Succinate. We therefore compared the pharmacological efficacy of Prednisolone with that of Prednisolone Sodium Succinate in-vitro using human peripheral blood mononuclear cells (PBMCs). PBMCs were obtained from 5 healthy subjects and 1 patient with pneumonia. The cells were incubated in the presence of concanavalin A and the cell growth was estimated by 3-(4,5-dimethyl thiazo-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Both Prednisolone and Prednisolone Sodium Succinate dose-dependently suppressed PBMC blastogenesis. Mean (s.d.) Prednisolone and Prednisolone Sodium Succinate IC50 (concentration of drug that gave 50% inhibition of cell growth) values were 580.0 (1037.9) and 3237.1 (4627.3) nM, respectively. The ratio of Prednisolone IC50/Prednisolone Sodium Succinate IC50 ranged from 0.005 to 0.230. Thus, Prednisolone Sodium Succinate potency was markedly lower than that of Prednisolone. After incubation of PBMCs with 100 microM Prednisolone Sodium Succinate, 22.7-42.9 microM Prednisolone was liberated into the culture medium, as determined by HPLC. The ratio of Prednisolone liberation from Prednisolone Sodium Succinate was not affected by the presence of fetal bovine serum or PBMC, or both, in the culture medium. These results suggested that the PBMC-suppressive effects of Prednisolone Sodium Succinate might be due, at least partially, to Prednisolone liberated from Prednisolone Sodium Succinate into the culture medium. Prednisolone Sodium Succinate can be converted to Prednisolone in the absence of serum or PBMCs, but the ratio of this conversion was very slow (t(1/2) > 4 days). Therefore, impairment of the enzymatic conversion of Prednisolone Sodium Succinate to Prednisolone in some pathological conditions such as liver diseases may result in attenuation of the clinical efficacy of Prednisolone Sodium Succinate.
Renato Cutrera - One of the best experts on this subject based on the ideXlab platform.
-
anaphylactic shock with methylPrednisolone Sodium Succinate in a child with short bowel syndrome and cow s milk allergy
Italian Journal of Pediatrics, 2017Co-Authors: Federica Porcaro, Alessandro Fiocchi, Maria Giovanna Paglietti, Antonella Diamanti, Francesca Petreschi, Alessandra Schiavino, Valentina Negro, Valentina Pecora, Renato CutreraAbstract:Medications with methyl-Prednisolone Sodium Succinate containing lactose, which potentially contains traces of cow’s milk proteins (CMP), could cause allergic reactions or compromise treatment of acute allergic reactions in sensitized patients. We describe the unusual case of a one-year-old child affected by short bowel syndrome and history of severe cow’s milk allergy (CMA) and anaphylactic reaction due to intravenous administration of methyl-Prednisolone Sodium Succinate (Solu-Medrol 40 mg, Pfizer). He was admitted to our hospital for severe respiratory failure and was initially treated with methyl-Prednisolone (Urbason 40 mg, Sanofi Aventis), then with methyl-Prednisolone Sodium Succinate (Solu-Medrol 40 mg, Pfizer). After the intravenous administration of second steroid, immediate anaphylaxis was recorded and treatment was stopped. Antihistamine and epinephrine were required and symptom resolution occurred. Children who are highly sensitive to milk may have severe allergic reactions also after exposure to CMP through a different administration route than the oral one. Patients who have food allergies need to pay particular attention to the prescription of drugs and their formulation.
-
Anaphylactic shock with methylPrednisolone Sodium Succinate in a child with short bowel syndrome and cow’s milk allergy
'Springer Science and Business Media LLC', 2017Co-Authors: Federica Porcaro, Alessandro Fiocchi, Maria Giovanna Paglietti, Antonella Diamanti, Francesca Petreschi, Alessandra Schiavino, Valentina Negro, Valentina Pecora, Renato CutreraAbstract:Abstract Background Medications with methyl-Prednisolone Sodium Succinate containing lactose, which potentially contains traces of cow’s milk proteins (CMP), could cause allergic reactions or compromise treatment of acute allergic reactions in sensitized patients. Case presentation We describe the unusual case of a one-year-old child affected by short bowel syndrome and history of severe cow’s milk allergy (CMA) and anaphylactic reaction due to intravenous administration of methyl-Prednisolone Sodium Succinate (Solu-Medrol 40 mg, Pfizer). He was admitted to our hospital for severe respiratory failure and was initially treated with methyl-Prednisolone (Urbason 40 mg, Sanofi Aventis), then with methyl-Prednisolone Sodium Succinate (Solu-Medrol 40 mg, Pfizer). After the intravenous administration of second steroid, immediate anaphylaxis was recorded and treatment was stopped. Antihistamine and epinephrine were required and symptom resolution occurred. Conclusion Children who are highly sensitive to milk may have severe allergic reactions also after exposure to CMP through a different administration route than the oral one. Patients who have food allergies need to pay particular attention to the prescription of drugs and their formulation
Inger Lilliehöök - One of the best experts on this subject based on the ideXlab platform.
-
Prednisolone in Dogs—Plasma Exposure and White Blood Cell Response
'Frontiers Media SA', 2021Co-Authors: Carl Ekstrand, Helena Pettersson, Ronette Gehring, Mikael Hedeland, Sara Adolfsson, Inger LilliehöökAbstract:Glucocorticoids such as Prednisolone are commonly used in dogs but there is sparse quantitative pharmacokinetic and pharmacodynamic information of this drug in this species. The objective of this study was to quantitatively characterize the concentration-effect relationship for Prednisolone in dogs on neutrophil and lymphocyte trafficking and cortisol suppression. Nine beagles, 2–12 years old and part of a group for teaching/research were used in a 4-way crossover experiment including two treatments, active or placebo, administered either per os (PO) or intravenously (IV). Plasma was analyzed for Prednisolone and cortisol using ultra-high performance liquid chromatography – tandem mass spectrometry. Leucocyte counts were performed in whole blood. Data was then analyzed by non-linear mixed effect modeling to estimate pharmacokinetic and pharmacodynamic parameters. After administration of Prednisolone Sodium Succinate IV, the typical value (between subject variation) for total body Prednisolone clearance was 1,370 ml/h·kg (13.4%). The volumes of the central and peripheral compartment were 2,300 ml/kg (10.7%) and 600 ml/kg (16.0%), respectively. The terminal plasma half-life was 1.7 h. The Prednisolone plasma concentration producing 50% of the maximum response was 10 ng/mL (90.3%), 22.5 ng/ml (52.3%) and 0.04 ng/mL (197.3%) for neutrophil, lymphocyte and cortisol response, respectively. The administered dose (1 mg/kg) increased neutrophil and decreased lymphocyte numbers but not over the entire dosage interval of 24 h, due to the short half-life. However, glucocorticoids have a wide range of responses. An anti-inflammatory response due to altered gene transcription might have a longer duration. Future studies on the anti-inflammatory potency together with data presented are needed to optimize future dosage recommendations in dogs